SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about company updates

28 Nov 2017 Evaluate

Glenmark Pharmaceuticals has informed that the Baddi unit of the company underwent an US FDA audit from November 6, 2017 to November 11, 2017. The USFDA issued seven observations through the form 483. The company is in the midst of providing a comprehensive response to the observations and would be replying to the FDA shortly on the observations. At this point in time, the company has informed that the Baddi unit contributes approximately 10 percent of the revenue of US sales.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma. Share Price

2209.85 14.85 (0.68%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: